News | October 01, 2014

Heart Hospital of Austin First in Texas to Offer New Heart Failure Monitoring System

October 1, 2014 — On Sept. 24, Heart Hospital of Austin became the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF system is the first and only U.S. Food and Drug Administration (FDA) -approved HF monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage HF.

The CardioMEMS HF system features a sensor that is implanted in the pulmonary artery (PA) during a non-surgical procedure to directly measure PA pressure. An increase in PA pressure can appear before overt symptoms of heart failure, which include shortness of breath, abdominal swelling, ankle edema and weight gain. The principal concept behind the CardioMEMS HF system is to treat the patient's heart failure based on changes in their direct PA pressure assessment. The system transmits daily sensor readings to their healthcare providers, allowing for personalized and proactive management to reduce the likelihood of hospitalization.

"We are pleased to be the first hospital in Texas to offer this innovative device, allowing heart failure patients to better manage their conditions," said Kunjan A. Bhatt, M.D., clinical cardiologist at Heart Hospital of Austin and with Austin Heart. "With the CardioMEMS HF system, we can monitor patients' conditions around the clock and immediately address any issues that may arise, keeping patients out of the hospital and improving their quality of life."

Heart failure occurs when the heart is unable to pump enough blood to meet the body's demands. According to the Centers for Disease Control and Prevention (CDC), more than 5.1 million Americans have heart failure, with 670,000 new cases diagnosed each year. Patients with heart failure are frequently hospitalized, experience a reduced quality of life and face a higher risk of death.

The CardioMEMS sensor is designed to last the lifetime of the patient, and it does not require batteries. Once implanted, the wireless sensor sends pressure readings to an external patient electronic system. There is no pain or sensation for the patient during the readings. The system allows patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.

Data from a clinical trial showed the CardioMEMS technology reduces heart failure hospital admissions by up to 37 percent. The CHAMPION trial studied the effectiveness of the CardioMEMS HF system in New York Heart Association (NYHA) class III heart failure patients who had been hospitalized for heart failure in the previous 12 months. Results of the trial demonstrated a statistically significant 28 percent reduction in the rate of heart failure hospitalizations at six months, and a 37 percent reduction in heart failure hospitalizations during an average follow-up duration of 15 months.

For more information: www.cardiomems.com

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Wearable monitors create patient generated health data, PGHD, that can help prevent acute care episodes in heart failure.

Wearable monitoring devices may offer a new tool to help prevent acute care episodes in heart failure.

Feature | Heart Failure| July 25, 2017 | Lola Koktysh
Despite their best efforts, many patients tend to develop heart failure after an acute event (e.g., a heart attack or
Overlay Init